OncoMatch/Clinical Trials/NCT06806930
Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
Is NCT06806930 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Neoadjuvant endocrine therapy and Neoadjuvant endocrine therapy for breast cancer stage i.
Treatment: Neoadjuvant endocrine therapy · Neoadjuvant endocrine therapy · Neoadjuvant endocrine therapy — The goal of this clinical trial is to determine how the duration of hormone blocking (endocrine) therapy given prior to surgery (called "neoadjuvant" treatment) affects breast cancer. The main questions the trial aims is answer are: 1. How breast cancer responds to endocrine therapy given prior to surgery? 2. To predict tumor pre-operative endocrine prognostic index (PEPI) score for subjects enrolled in cohort B or C Participants with early-stage breast cancer (Stage I-III) who are eligible for Neoadjuvant Endocrine Therapy (NET) will be enrolled in the study. Participants will: * receive endocrine therapy as part of regular care for breast cancer * consent to samples of blood and tissue evaluation to determine how endocrine therapy effects the tumor * participate in this research anywhere from 2 weeks to 1 year, depending on duration of endocrine therapy and when surgery will be performed
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (> 10% positive stained cells)
Estrogen receptor > 10% positive stained cells based on most recent tumor biopsy and documented by a local laboratory or medical record.
Required: HER2 (ERBB2) negative (negative)
HER2 negative or HER2 low breast cancer based on the most recent tumor biopsy and documented by a local laboratory or medical record. HER2 negative tumor is defined per American Society of Clinical Oncology and the College of American Pathologists guidelines, 2018.
Allowed: HER2 (ERBB2) low
Patients with HER2 low tumors are eligible as long as patients are not candidates for any HER2 directed therapy.
Disease stage
Required: Stage I, II, III
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- George Washington-Medical Faculty Associates · Washington D.C., District of Columbia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify